Testicular synovial sarcoma: a case report

Cancer Biology and Medicine

Volumn 9, Issue 4, 2012, Pages 274-276

  Nesrine, Mejri ^a   Sellami, Rym ^a   Doghri, Raoudha ^a   Rifi, Hela ^a   Raies, Henda ^a   Mezlini, Amel ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

Chemotherapy; Synovial sarcoma; Testis

Indexed keywords

DACARBAZINE; DOXORUBICIN; EPITHELIAL MEMBRANE ANTIGEN; GEMCITABINE; IFOSFAMIDE; PACLITAXEL;

ADULT; ARTICLE; CANCER RECURRENCE; CASE REPORT; CELL PROLIFERATION; CHROMOSOME ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; ECHOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; SCROTAL SWELLING; SPINDLE CELL; SYNOVIAL SARCOMA; TESTICULAR SYNOVIAL SARCOMA; TESTIS CANCER; THORAX PAIN;

EID: 84876309684     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2012.04.010     Document Type: Article

References (7)

1. Bergh P, Jeanne M, Gherlizionne F et al. Synovial sarcoma: Identifi cation of low and high risk groups. Cancer 1999; 85: 2596-2607.
2. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol 2008; 97: 314-320.
3. Fernebro J, Francis P, Eden P, et al. Gene expression profi les relate to SS18/SSX fusion type in synovial sarcoma. Int J Cancer 2006; 118: 1165-1172.
4. Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: A multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000; 18: 2087-2094.
5. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma: Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506-2511.
6. Lai JP, Rosenberg AZ, Miettinen MM, et al. NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target. Oncoimmunology 2012; 1: 1409-1410.
7. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial sarcoma cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-924.